Regardless of the cause of a disease, most diseases involve gene dysregulation. Omega Therapeutics is developing a new class of programmable, epigenomic, mRNA medicines designed to make specific epigenetic changes and correct abnormal gene expression to treat or cure diseases. We spoke to Mahesh Karande, president and CEO of Omega Therapeutics, about its pipeline of mRNA therapies, how they work, and its recently announced collaboration with Novo Nordisk to develop an epigenomic controller to treat obesity.
Combatting Superbugs and Emerging Viruses
How a Plant-Derived Gel Halts Bleeding in Seconds
Exploiting a Vulnerability in Cancers
Democratizing AI
A Rapid Onset Nasal Spray to Treat Mental Health Conditions
A Regenerative Medicine Company Puts Its Off-the-Shelf Vessel Replacements to the Test in Ukraine
Battling Resistance in Tumors with “Pan-Variant” Kinase Inhibitors
Treating Disease by Editing Genes in the Microbiome
Embracing the Promise of Natural Killer Cells in the Fight Against Cancer
Addressing Neurodegenerative Disease by Suppressing a Hyper Immune Response
Bringing Precision Medicine to Psychiatry
Attacking Neurodegenerative Diseases with Protein Degraders
Restoring Immune Activity While Suppressing Cancer Proliferation
A New Model for Preventing Life-Threatening Blood Clots
The Race to Live Forever
A Model for Moving from Breakthrough to Blockbuster
Building the Next-Generation of Cell and Gene Therapies
Building Small Molecule Drugs that Are Superior to Biologics
A New Class of Cancer Therapies Targets Solid Tumors with a Dual Action
A Pursuit of Off-The-Shelf CAR-T Therapies
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths